BALAXI PHARMACEUTICALS LIMITED has informed the Exchange about Investor Presentation
BALAXI · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Balaxi Pharmaceuticals filed its investor presentation for the quarter and year ended 31 March 2025. Consolidated revenue grew 21% in FY25, supported by strong performance in both Africa and Latin America, with gross margins staying healthy despite inflationary and employee cost pressures. The company secured 85 new product registrations during the year, taking its total portfolio to 915 products across seven countries, with over 300 additional registrations in the pipeline. A major milestone is the completion of construction at its first pharmaceutical formulation plant in Jadcherla, Hyderabad, with operational qualification and validation expected by end of June 2025, marking a shift from an 'Asset Light' to an 'Asset Right' model. Management outlined a forward roadmap targeting expansion into Ecuador, Chile, South-East Asia, and CIS markets, while raising funds via a INR 47.57 crore preferential issue to fund capex.
The strong revenue growth, resilient margins, and imminent commissioning of the in-house manufacturing facility point to potential margin expansion and better cost control going forward. Investors should watch for FY26 operational updates on the Hyderabad plant and new geographic launches, which could act as near-term catalysts for the stock.